Enhancing the efficacy of glycolytic blockade in cancer cells via RAD51 inhibition.

Autor: Wilson JJ; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Chow KH; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Labrie NJ; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Branca JA; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Sproule TJ; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Perkins BRA; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Wolf EE; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Costa M; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Stafford G; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Rosales C; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Mills KD; b Cyteir Therapeutics , Cambridge , MA , USA., Roopenian DC; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA., Hasham MG; a Research Department , The Jackson Laboratory , Bar Harbor , Maine , USA.

Publikováno v: Cancer biology & therapy [Cancer Biol Ther] 2019; Vol. 20 (2), pp. 169-182. Date of Electronic Publication: 2018 Sep 05.